RCT223 / ReCode Therap - LARVOL DELTA

ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference (Businesswire) - "ReCode Therapeutics...presented new preclinical data today from the Company’s inhaled mRNA-based therapeutic program for cystic fibrosis (CF) during an oral poster session at the 2021 North American Cystic Fibrosis Conference (NACFC)....'These data validate our mRNA-based approach to treating CF which leverages our powerful LNP platform and offers the potential to restore CFTR function in CF patients'....'Today’s data support the continued development of an inhaled mRNA therapy for the treatment of CF, and we look forward to advancing this program toward an IND submission.'"

Preclinical • Cystic Fibrosis • Genetic Disorders

ReCode Therapeutics to Present Preclinical Data from mRNA-based Program for Cystic Fibrosis at Upcoming Virtual 2021 North American Cystic Fibrosis Conference (Businesswire) - "ReCode Therapeutics...today announced that it will present preclinical data from its mRNA-based therapeutic program for cystic fibrosis (CF) in a poster presentation at the upcoming 2021 North American Cystic Fibrosis Conference (NACFC) to be held virtually from November 2-5, 2021."

Preclinical • Cystic Fibrosis

ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million (Businesswire) - "ReCode Therapeutics...today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital....The proceeds from the Series B financing will be used to drive ReCode’s lead programs in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into human clinical studies, expand the pipeline of treatments for patients with life-limiting genetic respiratory diseases, advance its LNP platform for organ-specific delivery of RNA and gene correction therapies and increase internal manufacturing capabilities."

Financing • Cystic Fibrosis

ReCode Therapeutics Presents Preclinical Data Using SORT-LNP and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS) (Businesswire) - "ReCode Therapeutics...today presented encouraging preclinical data from the Company’s RNA-based molecular therapy program for cystic fibrosis (CF) delivered using the Company’s LNP platform, including three-component Zwitterionic Amino Lipids (ZALs) and five-component selective organ targeting lipid nanoparticles (SORT-LNPTM), during an oral session at the 44th European Cystic Fibrosis Conference...These findings are an important step as we advance our novel CF program closer to Investigational New Drug (IND)-enabling studies and an IND submission to the FDA in 2022...RCT223 was shown to restore CFTR function for at least 72 hours in patient-derived hBE cells after a single administration. With twice-weekly repeated doses, CFTR functional levels continued to increase."

IND • Preclinical • Cystic Fibrosis